Coming out of Covid, the vaccine market appeared to experience a renaissance as the innovations of the pandemic unleashed new ...
Genmab is culling a trio of early oncology assets to focus on upcoming milestones for its late-stage programs that ...
Gilead said its Covid-19 antiviral Veklury had $692 million in third-quarter sales, far more than the $270 million Wall ...
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Coherus is resuming the supply of its ...
Aurinia Pharmaceuticals is reducing 45% of its workforce and is bringing in a new board member as part of a broader restructuring. The company ...
Plus, news about ADC Therapeutics, Celldex and Viracta Therapeutics: Geron inks up to $375M royalty and debt deal: The company now has a $125 million deal ...
California voters supported a state ballot measure on Tuesday that would increase oversight around the 340B federal drug ...
Despite the rise of a vaccine skeptic in the campaign of US presidential election winner Donald Trump, GSK CEO Emma Walmsley ...
Denali revealed new topline data Wednesday for an early-stage program that's a part of the FDA’s Operation Warp Speed for rare diseases. The program, DNL126, is an ...
Demis Hassabis is pursuing one of the boldest efforts of bringing AI into biotech, building out the Alphabet-backed startup Isomorphic Labs over the past three ...
Moderna revealed the consequences of its late start in the market for RSV vaccines, reporting just $10 million in third-quarter sales from the new shot. Those numbers are a fraction ...
After a year of customer pullbacks, biologics CDMO Avid Bioservices will be taken private by GHO Capital Partners and Ampersand Capital Partners in a deal worth $1.1 billion. “In evaluating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback